Published :
Tables : 49
Figures : 44
Category : Healthcare
No. of Pages : 226
Report Code : HC-U3406
Neuropathic Pain Management Market Overview: Neuropathic pain is a chronic pain condition caused owing to infection, trauma and other such dysfunctional systems in the nerves. Primary neuropathic pain syndromes include postherpetic neuralgia, painful neuropathy, painful traumatic mononeuropathy, central pain syndromes, complex regional pain syndrome and postsurgical pain syndromes. Anticonvulsants, antidepressants like tricyclic antidepressants and anaesthetics are generally prescribed for neuropathic pain. Furthermore, antidepressants like nortriptyline and amitriptyline are primarily used for managing neuropathic pain. Additionally, the growing prevalence of chronic diseases like diabetes and cancer shall bolster the neuropathic pain management market growth. However, a dearth of awareness pertaining to the implementation of the procedure in underdeveloped regions shall impede the proliferation of the market. Conversely, rise in the number of pain centres shall boost the augmentation of the market. Neuropathic Pain Management Market Segmentation: By Drug Class • Gabapentinoids • Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) • Tricyclic Antidepressants • Combination Drugs • Others By Route of Administration • Oral • Topical • Transdermal By Indications • Diabetic Neuropathy • Trigeminal Neuralgia • Post-Herpetic Neuralgia • Chemotherapy-Induced Peripheral Neuropathy • Other Indications By Distribution Channel • Hospital Pharmacies • Retail/ Drug Stores • Online Pharmacies By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa The market is categorised into drug class, indication, distribution channel and region. The drug class segment is classified into tricyclic antidepressants, anticonvulsants, SNRIs, capsaicin cream, local anaesthesia, opioids, steroids and others. The tricyclic antidepressants segment is predicted to hold the largest neuropathic pain management market share during the forecasted timeframe. The indication segment is fragmented into diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others. The distribution channel segment is diversified into retail pharmacies, hospital pharmacies and online pharmacies. The hospital pharmacies segment is anticipated to lead the market owing to growing investments for hospitals in developed and underdeveloped nations. Regional Analysis: The North America region is expected to dominate the market and this can be credited to increased disposable income, rising geriatric population, a strong presence of key market players in the region. Competitive Landscape: The major players included are: • Baxter International Inc. • Biogen Inc • Bristol-Myers Squibb and Company • Assertio Therapeutics Inc. • Eli Lily and Company • GlaxoSmithKline PLC • Johnson & Johnson Services Inc. • Pfizer Inc. • Sanofi S.A. • Merck & Co. • Teva Pharmaceutical Industries Ltd. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global neuropathic pain management market by drug class, by indications, by route of administration, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers, and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Neuropathic pain is a chronic pain condition caused owing to infection, trauma and other such dysfunctional systems in the nerves. Primary neuropathic pain syndromes include postherpetic neuralgia, painful neuropathy, painful traumatic mononeuropathy, central pain syndromes, complex regional pain syndrome and postsurgical pain syndromes. Anticonvulsants, antidepressants like tricyclic antidepressants and anaesthetics are generally prescribed for neuropathic pain.
Furthermore, antidepressants like nortriptyline and amitriptyline are primarily used for managing neuropathic pain. Additionally, the growing prevalence of chronic diseases like diabetes and cancer shall bolster the neuropathic pain management market growth. However, a dearth of awareness pertaining to the implementation of the procedure in underdeveloped regions shall impede the proliferation of the market. Conversely, rise in the number of pain centres shall boost the augmentation of the market.
Neuropathic Pain Management Market Segmentation:
By Drug Class • Gabapentinoids • Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) • Tricyclic Antidepressants • Combination Drugs • Others By Route of Administration • Oral • Topical • Transdermal By Indications • Diabetic Neuropathy • Trigeminal Neuralgia • Post-Herpetic Neuralgia • Chemotherapy-Induced Peripheral Neuropathy • Other Indications By Distribution Channel • Hospital Pharmacies • Retail/ Drug Stores • Online Pharmacies By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa
The market is categorised into drug class, indication, distribution channel and region. The drug class segment is classified into tricyclic antidepressants, anticonvulsants, SNRIs, capsaicin cream, local anaesthesia, opioids, steroids and others. The tricyclic antidepressants segment is predicted to hold the largest neuropathic pain management market share during the forecasted timeframe. The indication segment is fragmented into diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others. The distribution channel segment is diversified into retail pharmacies, hospital pharmacies and online pharmacies. The hospital pharmacies segment is anticipated to lead the market owing to growing investments for hospitals in developed and underdeveloped nations.
Regional Analysis:
The North America region is expected to dominate the market and this can be credited to increased disposable income, rising geriatric population, a strong presence of key market players in the region.
Competitive Landscape:
The major players included are: • Baxter International Inc. • Biogen Inc • Bristol-Myers Squibb and Company • Assertio Therapeutics Inc. • Eli Lily and Company • GlaxoSmithKline PLC • Johnson & Johnson Services Inc. • Pfizer Inc. • Sanofi S.A. • Merck & Co. • Teva Pharmaceutical Industries Ltd.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global neuropathic pain management market by drug class, by indications, by route of administration, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers, and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Neuropathic Pain Management Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Neuropathic Pain Management Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Neuropathic Pain Management Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Neuropathic Pain Management Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Gabapentinoids 7.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 7.3. Tricyclic Antidepressants 7.4. Combination Drugs 7.5. Others 8. Neuropathic Pain Management Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Oral 8.2. Topical 8.3. Transdermal 9. Neuropathic Pain Management Market, By Indications Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Diabetic Neuropathy 9.2. Trigeminal Neuralgia 9.3. Post-Herpetic Neuralgia 9.4. Chemotherapy-Induced Peripheral Neuropathy 9.5. Other Indications 10. Neuropathic Pain Management Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Hospital Pharmacies 10.2. Retail/ Drug Stores 10.3. Online Pharmacies 11. North America Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. Baxter International Inc. 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Biogen Inc 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Bristol-Myers Squibb and Company 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Assertio Therapeutics Inc. 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Eli Lily and Company 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. GlaxoSmithKline PLC 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Johnson & Johnson Services Inc. 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Pfizer Inc. 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Sanofi S.A. 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Merck & Co. 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Teva Pharmaceutical Industries Ltd. 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Neuropathic Pain Management Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Neuropathic Pain Management Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Neuropathic Pain Management Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Neuropathic Pain Management Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Gabapentinoids 7.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 7.3. Tricyclic Antidepressants 7.4. Combination Drugs 7.5. Others
8. Neuropathic Pain Management Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Oral 8.2. Topical 8.3. Transdermal
9. Neuropathic Pain Management Market, By Indications Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Diabetic Neuropathy 9.2. Trigeminal Neuralgia 9.3. Post-Herpetic Neuralgia 9.4. Chemotherapy-Induced Peripheral Neuropathy 9.5. Other Indications
10. Neuropathic Pain Management Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Hospital Pharmacies 10.2. Retail/ Drug Stores 10.3. Online Pharmacies
11. North America Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028
12. Latin America Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028
13. Europe Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028
14. Asia Pacific Neuropathic Pain Management Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. Baxter International Inc. 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Biogen Inc 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Bristol-Myers Squibb and Company 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Assertio Therapeutics Inc. 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Eli Lily and Company 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. GlaxoSmithKline PLC 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Johnson & Johnson Services Inc. 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Pfizer Inc. 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Sanofi S.A. 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Merck & Co. 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Teva Pharmaceutical Industries Ltd. 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics